-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HCV-IN-29
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1009119-83-8.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1009119-83-8 |
| Description | HCV-IN-29 is an inhibitor of hepatitis C virus (HCV). (Exacted from patent US8329159B2, compound 1e) |
Product Information
| Synonyms | 4,4'-Bis(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)-1,1'-biphenyl tetrahydrochloride; 5,5'-[1,1'-Biphenyl]-4,4'-diylbis[2-(2S)-2-pyrrolidinyl-1H-imidazole] Hydrochloride; 5,5'-(4,4'-Biphenyldiyl)bis{2-[(2S)-2-pyrrolidinyl]-1H-imidazole} tetrahydrochloride |
| IUPAC Name | 2-[(2S)-pyrrolidin-2-yl]-5-[4-[4-[2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazole;tetrahydrochloride |
| Molecular Weight | 570.38 |
| Molecular Formula | C26H32Cl4N6 |
| Canonical SMILES | C1CC(NC1)C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6.Cl.Cl.Cl.Cl |
| InChI | InChI=1S/C26H28N6.4ClH/c1-3-21(27-13-1)25-29-15-23(31-25)19-9-5-17(6-10-19)18-7-11-20(12-8-18)24-16-30-26(32-24)22-4-2-14-28-22;;;;/h5-12,15-16,21-22,27-28H,1-4,13-14H2,(H,29,31)(H,30,32);4*1H/t21-,22-;;;;/m0..../s1 |
| InChIKey | AYOXSBJGFNPGNK-VDUNKYASSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 547 |
| Exact Mass | 570.141306 |
| Target | HCV |